Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
This study aimed to assess the fibrinolytic inhibitors and their association with thrombosis in Behçet disease. Thrombin activatable fibrinolysis inhibitor (TAFI) (P < 0.001) and plasminogen activator inhibitor-1 (PAI-1) levels (P = 0.022) were significantly higher in 79 patients than in 84 controls. No significant differences were observed in CPB2 (TAFI) Thr325Ile and SERPINE1 (PAI1) 4G/5G polymorphism distribution between patients and controls. TAFI activity levels were significantly higher in patients with thrombosis than in those without thrombosis (P = 0.024). In conclusion, the increased TAFI levels in Behçet disease could contribute to the increased risk of thrombosis observed in these patients.
Ricart
José M
JM
Dermatology Service, La Fe University Hospital, Valencia, Spain.
Ramón
Luis A
LA
Vayá
Amparo
A
España
Francisco
F
Santaolaria
Maria-Luisa
ML
Todolí
José
J
Castelló
Remedios
R
Fontcuberta
Jordi
J
Estellés
Amparo
A
D000328:Adult; D001528:Behcet Syndrome / Q000097:blood* / Q000235:genetics; D001786:Blood Glucose / Q000032:analysis; D025901:Carboxypeptidase B2 / Q000097:blood*; D005260:Female; D005342:Fibrinolysis; D020022:Genetic Predisposition to Disease; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D011110:Polymorphism, Genetic; D013927:Thrombosis / Q000097:blood* / Q000235:genetics
D001786:Blood Glucose; D008055:Lipids; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human; D025901:Carboxypeptidase B2